Other potentially

helpful effects of acetazolamide for acclimatization are that it decreases cerebrospinal fluid production in addition to inhibiting antidiuretic hormone secretion helping to counteract fluid retention at high altitude. Other drugs including ginko biloba[8, 9] spironolactone,[17] dexamethaosone,[1] sumaptriptan[18] and non-steroidal anti-inflammatory drugs[19] have been tested in the prevention of AMS; and some of these have been shown to be efficacious.[18, 19] But acetazolamide continues MS-275 concentration to be the superior drug for AMS prevention due to its proven efficacy over the years in a large number of trials with an acceptable side-effect profile. Another important use of acetazolamide in the mountains is in the prevention of periodic breathing at high altitude which is a very common problem sometimes triggering anxiety attacks. Acetazolamide decreases the hypoxemic spells during sleep and successfully treats this problem in most instances.[20]

In conclusion, sojourners ascending high altitude need to be encouraged to go up gradually without the use of drugs, including acetazolamide to enhance acclimatization. However, in certain instances, acetazolamide may indeed be required. By publishing these two articles, the journal has given due importance to this commonly used drug for AMS. The author states he has no conflicts of interest to declare. “
“The aim of the study was to assess the impact of electronic checklists in enhancing sexually transmitted infection (STI) screening in routine HIV care. This was a retrospective cohort see more study. In two HIV clinics, new STIs were recorded for three consecutive 12-month periods between 2009 and 2012 in a cohort of 882 HIV-infected patients. These three years coincided with the introduction of enhanced STI screening based on prompts within the electronic patient record (EPR) system. The number of diagnoses and the incidence

of STIs more than doubled between 2010–2011 and 2011–2012 in both men who have sex with men (MSM) [from 18 of 115 (15%) to 42 of 132 (32%), a rise in STI incidence from 15.6 to 31.8/100 person-years; P < 0.001] and heterosexual patients [from six of 716 (0.8%) to 19 of 749 (2.5%), a rise in STI incidence from 0.8 to 2.5/100 person-years; P < 0.005]. learn more The rise was significant in MSM for infections with chlamydia [from seven of 115 (6%) to 14 of 132 (11%), a rise in incidence from 6.0 to 10.6/100 person-years; P < 0.05], gonorrhoea [from five of 115 (4%) to 12 of 132 (9%), a rise in STI incidence from 4.3 to 9.1/100 person-years; P < 0.05] and early syphilis [from four of 115 (3%) to 13 of 132 (10%), a rise in incidence from 3.5 to 9.8/100 person-years; P < 0.001], but not for hepatitis C virus (HCV) and Lymphogranuloma venereum (LGV) infections. The rise was significant in heterosexual patients for infection with chlamydia [from four of 716 (0.6%) to 13 of 749 (1.7%), a rise in incidence from 0.6 to 1.7/100 person-years; P < 0.